Viro-Immunologic Effects of Interrupting Maraviroc in Patients Failing a Maraviroc-containing Antiretroviral Treatment (The Maraviroc Short-Stop Study) [Studio degli effetti immuno-virologici dell'interruzione di Maraviroc nei pazienti che stanno fallendo un regime contenente Maraviroc]

Trial Profile

Viro-Immunologic Effects of Interrupting Maraviroc in Patients Failing a Maraviroc-containing Antiretroviral Treatment (The Maraviroc Short-Stop Study) [Studio degli effetti immuno-virologici dell'interruzione di Maraviroc nei pazienti che stanno fallendo un regime contenente Maraviroc]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Maraviroc (Primary) ; Abacavir; Atazanavir; Darunavir; Didanosine; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; Etravirine; Fosamprenavir; Lamivudine; Lamivudine/abacavir; Lamivudine/zidovudine; Lopinavir; Nevirapine; Raltegravir; Ritonavir; Saquinavir; Stavudine; Tenofovir disoproxil fumarate; Tipranavir; Zidovudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms The Maraviroc Short-Stop Study
  • Most Recent Events

    • 25 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top